Europe Liver Disease Treatment Market

Europe Liver Disease Treatment Market Size (2022 to 2027)

The size of the Liver Disease Treatment Market in the European region is expected to reach USD 4.01 billion by 2027 from USD 2.32 billion in 2022, growing at a CAGR of 11.56% during the forecast period.

The percentage of the aged population diagnosing with liver-related diseases is significantly increasing in Europe and is primarily driving the growth of the European liver disease treatment market. Europe is among one of the leading markets for Liver Disease Treatment Drugs. As per a report, liver cirrhosis causes 170,000 deaths in Europe annually. Within Europe, Germany, France, and the United Kingdom account for the largest liver disease treatment market share.

Various technological advancements in the imaging techniques, Y-O-Y increase in the patients diagnosing with the liver diseases further contribute to the growth of the market. The increasing number of mergers and acquisitions that are happening between the companies is predicted to shape the face of the market better during the forecast period. The license expiration of a few drugs and robust pipeline drugs for the treatment of liver diseases is adding fuel to the market.

Strict regulations of the FDA, MHRA in approving the new drugs, and high costs required for the development of new drugs, and the high costs associated with the treatment for liver diseases are expected to hamper the market growth to a specific limit.

This research report on the Europe Liver Disease Treatment Market has been segmented and sub-segmented into the following categories:

By Treatment Modality:

• Antiviral
• Vaccines
• Chemotherapy
• Immunosuppressive Agents
• Corticosteroids

By Disease Type:

• Hepatitis
• Non-Alcoholic Fatty Liver Disease
• Alcohol-Induced
• Liver Cancer

By Country:

• United Kingdom
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Rest of Europe

Regional Analysis:

Geographically, the European liver disease treatment market stands second, following North America in leading the global liver disease treatment market. It is due to viral hepatitis, genetic disorders, unhealthy diet, and excessive intake of alcohol.

Germany, UK, and France account for significant shares of the liver disease treatment market in the region. The growing number of liver disease cases because of the vast drinking population in Europe and increasing obesity and growing new clinical needs in liver diseases are likely to accelerate market growth. The Germany market is rising due to factors like excess intake of over-the-counter high dosage drugs, reimbursement policies for liver diseases in the healthcare sector, government, and other private organizations bring out the awareness by organizing programs regarding liver disease treatment which propels the market during the analysis period. Alcohol consumption is considered to cause 20%-50%of cirrhosis of the liver, and around 13% of the population across the globe, i.e., more than 600 million adults, are obese according to World Health Organization. Moreover, Cirrhosis can cause 170,000 deaths in Europe every year.

Companies playing a vital role in the European Liver Disease Treatment Market profiled in the report are Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland), Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer Schering AG (Germany) and AstraZeneca (United Kingdom).